A number of gene therapies are in late-stage clinical trials and expected to reach the market in the next several years.
Keeping up with quality is key for the industry throughout the supply chain. Quality must be ensured from the earliest phases of development.
The (bio)pharmaceutical industry is becoming a high-technology sector with success directly linked to innovation.
Lack of effective management of the outbound distribution of clinical trial materials can negatively impact study outcomes.
The contract manufacturing market for antibody-drug conjugates has huge potential, but an extraordinary range of capabilities is essential to be in the game.
Efficient development of optimal routes and manufacturing processes for the production of increasingly complex small molecule APIs requires extensive expertise.
Following a string of approvals, biosimilars are positioned to go the way of generics.
Call it the automation of everything — a hands-off approach will permeate supply chains in the near future.
Potassium channels are present in nearly all types of cells and involved in most physiological functions.
Reducing the time, cost and environmental footprint of manufacturing processes continues to be a major driver of technology development.
Single-use technologies (SUTs) have introduced a broad range of cost and operating efficiencies to bioprocessing operations.
Anticipating 2018 technologies and their impact.
The importance and impact on innovative technologies introduced in 2017.
.svg)
